Nasdaq · Healthcare
Guardant Health, Inc. (GH)
As-reported financials and recent SEC filings for Guardant Health, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$982.0M
Net income
$-416.3M
Net margin
-42.4%
Diluted EPS
$-3.32
ROE
419.2%
P/E (TTM)
—
Market cap
$19.79B
Debt / equity
-15.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $982.0M | $739.0M | $563.9M | $449.5M | $373.7M |
| Gross profit | $633.0M | $449.2M | $336.9M | — | — |
| Operating income | $-437.2M | $-443.6M | $-564.7M | $-544.4M | $-411.0M |
| Net income | $-416.3M | $-436.4M | $-479.4M | $-654.6M | $-384.8M |
| Diluted EPS | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →1442026-06-26
View on EDGAR →1442026-06-24
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-22
View on EDGAR →1442026-06-22
View on EDGAR →Go deeper on GH
Search Guardant Health, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.